Research programme: serine hydrolase inhibitors - Abide Therapeutics

Drug Profile

Research programme: serine hydrolase inhibitors - Abide Therapeutics

Latest Information Update: 06 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; Oxford University Hospitals NHS Trust; University of California, San Diego; University of Oxford
  • Class Small molecules
  • Mechanism of Action Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Down syndrome
  • Research Brain disorders

Most Recent Events

  • 04 Nov 2014 Abide Therapeutics enters into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust for the development of MAGL inhibitors for Brain disorders
  • 04 Nov 2014 Early research in Brain disorders in United Kingdom (unspecified route)
  • 16 Jul 2013 Abide Therapeutics and University of California, San Diego receive grant from Cure Alzheimer's Fund to finance development of serine hydrolase inhibitors for Down syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top